Technical development of pharmaceutical and chemical products, cargo transportation and real estate development.
Company information disclosure newspaper: china securities journal and shanghai securities news Historical North China Pharmaceutical Group Co., Ltd. is the largest pharmaceutical enterprise in China, located in Shijiazhuang, the capital of Hebei Province. North China Pharmaceutical Factory, the predecessor of the company, is a key construction project during the first five-year plan period in China. It consists of an antibiotic factory, a starch factory and a medical glass factory imported from the former Democratic Republic of Germany in the 156 key project aided by the former Soviet Union. Construction started on June 1953, with a total investment of 75.88 million yuan, and was put into operation on June 1958. The establishment of North China Pharmaceutical Factory initiated the history of large-scale production of antibiotics in China, ended the history of China's dependence on imported penicillin and streptomycin, and the situation of lack of doctors and medicines was obviously improved.
Since its establishment more than 50 years ago, Huayao has been operating steadily, expanding gradually, expanding its business scope, increasing its sales volume and maintaining excellent performance. Its main economic indicators have been in the forefront of the same industry in China. Compared with when it was put into production, its business scope expanded from simple pharmacy to biology, chemicals, pesticides, commerce and other fields, and its main products increased from 5 to more than 430 varieties, and from a factory with a single property right structure to more than 30 subsidiaries, with diversified products. Huabei Pharmaceutical Co., Ltd. is a joint-stock enterprise invested by the former Huabei Pharmaceutical Factory with all its production and operation assets. It was established by public offering on 1992. 1994, Huayao shares were listed on the Shanghai Stock Exchange. At present, the proportion of state equity of the company is 59.87%, which is held by Huayao Group Company authorized by Hebei provincial government.
Huayao Co., Ltd. has 7 branches and 13 subsidiaries. Write and VC, VB 12.
The main products are raw materials and preparations of antibiotics and health products such as penicillin, streptomycin, oxytetracycline, lincomycin, semi-synthetic penicillin and cephalosporin, as well as nearly 100 varieties of VB 12, medical glass products, organic solvents, starch and sugar.
Among the main products, 19 varieties adopted international standards and foreign advanced standards to organize production, 6 products won the national quality award, and 28 varieties won the title of quality products at or above the provincial level. The production technical indicators of main antibiotic raw materials are in a leading position in China. Huayao Group has 27 subsidiaries, among which North China Pharmaceutical Co., Ltd., a listed company, is its largest holding subsidiary, with 12 subsidiaries. Huayao Co., Ltd. 1992 was reorganized and established, 1993 was raised by the society, and 1994 was listed and traded. In 2000, according to the needs of operation and management, Huayao Group established three business divisions: antibiotic raw materials, preparation drugs and starch sugar VB 12, and incorporated the subsidiaries or workshops that produce and operate the above three products into the management of the business divisions. Through the listing of traditional Chinese medicine, a total of 654.38+0.07 billion yuan of social funds were raised. Huayao actively attracted foreign investment, established Sino-foreign joint ventures 16, and accumulated foreign investment of 70 million US dollars.